Development↦Ethics and Laws↦Swissmedic Application↦Approval Medicinal Products
What is it? Why is it important?
For studies with an Investigational Medicinal Product (IMP), Swissmedic acknowledges the receipt of an application dossier within 7 days.
Swissmedic makes a formal evaluation whether the application dossier is complete, or if documents are:
- Missing, and/or
- Incomplete, and/or
- Not correctly filed
In the event of an incomplete dossiers the SP-INV is asked to update the dossier within a given deadline.
Swissmedic reaches a decision
- Within 30 days after acknowledging the receipt of the formally correct application dossier
- It can be extended by a maximum of 30 days if the IMP:
- Has never been tested in humans (first in man, phase I studies); or
- Is manufactured based on new production procedures: or
- Is not yet known to Swissmedic
For category C studies with an IMP capable of emitting ionising radiation, Swissmedic has up to 60 days to reach a decision.
More
If prior to approval, Swissmedic still has open issues regarding the application dossier, they will forward a preliminary decision letter listing what documents must still be:
- Submitted and/or
- Changed / adapted
Consequently, the application timeclock is stopped until all requested documents are forwarded and/or all requested changes are made.
A study that has been rejected by Swissmedic cannot be re-submitted. Any required adaptations would result in a new study and totally new submission.
Approval timelines for studies using an IMP & (I)MD combination (in vitro), depends on the conformity assessment of each product (e.g. consult Swissmedic tables regarding potential combination).
What do I need to do?
Once submitted to Swissmedic, the study is given a unique reference number. This number is included in all future Swissmedic correspondence.
If Swissmedic requires additional information or changes to the application dossier, as a SP-INV submit:
- A cover letter
- An updated CTA, if required
- Additionally required documents and/or information
- Required modifications (e.g. to submitted documents)
The study can only start after Swissmedic, the Ethics Committee (EC), and if applicable, the Federal Office of Public Health (FOPH) have approved the study.
After approval the SP-INV ensures that:
- The Swissmedic reference number is included in all future correspondence
- A robust document tracking system is in place (e.g. document identification)
- Modifications made to approved documents are re-submitted for approval prior to implementation (e.g. including EC approval)
File Swissmedic correspondence and approval documents in the TMF, and if applicable in the ISF of participating study sites.
More
After Swissmedic and EC approval, there is a deadline of 2-years for the enrolment of a first participant. The study will be interrupted if no participants are enrolled during that time period. Enrolment can only restart if a deadline extension is granted. An extension can be submitted before the deadline expires.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissmedic – see in particular
- Human medicine / Clinical trials / Clinical trials on medicinal products
- Medical devices / Clinical trials / combined studies
- Services & Lists / eGOV services
- Services & Lists / submissions
Swiss Law
ClinO – see in particular articles
- Art. 23 Coordination in authorisation procedures
- Art. 23a Deadline for enrolment of the first participant
- Art. 30 Exemption from authorisation
- Art. 32 Review areas
- Art. 33 Procedure and deadlines
TPA – see in particular article
- Art. 54 Mandatory authorisation